Riskpilot← Back to searchSign inGet full accessPharmEng Nordic ApS
APSActiveCVR 43181033Bredgade 20A, 2. tvAll other professional, scientific and technical activities n.e.c. · NACE 7499Est. 20224 employees
Revenue 2025
DKK 296K
-66% vs 2024
EBITDA margin
-372.5%
-26% vs 2024
Equity ratio
-648.8%
Financial strength
Net profit 2025
DKK -1,1M
-27% vs 2024
| Revenue | DKK 296K | -66% |
| EBITDA | DKK -1,1M | -26% |
| Net profit | DKK -1,1M | -27% |
| Total assets | DKK 487K | -52% |
| Equity | DKK -3,2M | -54% |
| Employees | 4 | — |
Legal name
PharmEng Nordic ApS
CVR number
43181033
Legal form
Anpartsselskab
NACE code
7499 · All other professional, scientific and technical activities n.e.c.
Founded
1. april 2022
Share capital
DKK 40.000
Employees
4 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet kan tegnes af én direktør.
Company purpose
Selskabets formål er at yde konsulentbistand til life science industrien.
Address
Bredgade 20A, 2. tv
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 2.016 | 583 | 870 | 296 |
| Staff expenses | -936 | -1.526 | -1.746 | -1.398 |
| EBITDA | -278 | -943 | -876 | -1.102 |
| Depreciation & amort. | -0 | -0 | -0 | -0 |
| EBIT | -278 | -943 | -876 | -1.102 |
| Net financials | 2 | 2 | 0 | -7 |
| Profit before tax | -276 | -941 | -876 | -1.109 |
| Tax | -0 | -0 | -0 | -0 |
| Net profit | -276 | -941 | -876 | -1.109 |
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 2.665 | 1.243 | 1.011 | 487 |
| Equity | -236 | -1.177 | -2.053 | -3.162 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 2.902 | 2.421 | 3.065 | 3.649 |
| Total debt | 2.902 | 2.421 | 3.065 | 3.649 |
EBITDA margin
-372.5%
This company
15.8%
Market median
-2458% vs market
20222025
Equity ratio
-648.8%
This company
38.2%
Market median
-1798% vs market
20222025
Return on equity
-110866500.0%
This company
18.4%
Market median
-602535426% vs market
20222025
Net profit margin
-374.8%
This company
8.1%
Market median
-4727% vs market
20222025
Asset turnover
0.61×
This company
1.12×
Market median
-46% vs market
20222025
Debt / equity
1.15×
This company
0.62×
Market median
-85% vs market
20222025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-04-01 – 2022-12-31
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
MC Management | Management | 2025 |
OC Management | Management | 2025 |
AK Founder | Founder | 2022 |
OT Management | Management | 2025 |
| Former (2) | ||
SC Management | Management | 2022 – 2025 |
DV Management | Management | 2022 – 2022 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2025 | |
| Individual | 100% | 100% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of PharmEng Nordic ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mathieu Charles Louis Roger | Management | 0 companies |
| Olivier Claude Gillot | Management | 0 companies |
| Steven Colin Davy | Management | 0 companies |
| Alan Kwok-Hung Kwong | Founder | 0 companies |
| Dharti Virendrakumar Pancholi | Management | 0 companies |
| Olivier Tambuzzo | Management | 0 companies |